Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727810 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL18760245 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL9503623 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL13176885 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL9507409 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL14556011 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL16748040 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL13296276 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL19227160 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL14147720 | 0.94 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051708-A2 | EPITOPE REDUCTION THERAPY | ISIS Innovation Limited (GB) | 2009-04-29 | — | — | EP | claimed |
| WO-2008012555-A2 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2008-01-31 | — | — | WO | claimed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-9682990-B2 | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160318946-A1 | ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| WO-2016110702-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | ISIS INNOVATION LIMITED (GB) | 2016-07-14 | — | — | WO | disclosed |
| US-9328073-B2 | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150148370-A1 | ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2015-05-28 | — | — | US | disclosed |
| WO-2012162513-A2 | ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | WO | disclosed |
| US-6136790-A | MULTIETHER COMPOUNDS AS ANTITICKING AGENTS | GLYCOREX AB (SE) | 2000-10-24 | — | — | US | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| EP-0671408-A2 | Carbohydrate mimetics having anti-adhesive properties | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| WO-1991002741-A1 | SUGAR ALCOHOL DERIVATIVES, A PROCESS FOR PREPARING 3-DEOXY-2-OCTULOSONIC ACID AND 3-DEOXY-2-HEPTULOSONIC ACID COMPOUNDS AND DERIVATIVES | RIJKSUNIVERSITEIT TE LEIDEN (NL) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | LMNA 4516/4885L3MBTL1 4543/4885TDP1 4598/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | LMNA 2930/4885L3MBTL1 3119/4885TDP1 3426/4885 |
| US-20160318946-A1 | ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS | TOP1, TOP2A, TOP2B | LMNA 664/4885L3MBTL1 4386/4885TDP1 15/4885 |
| US-20150148370-A1 | ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS | TOP1, TOP2A, TOP2B | LMNA 664/4885L3MBTL1 4386/4885TDP1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.